Abstract:Background: Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer with poor prognosis. Adoptive cell therapy using engineered T-cell receptors (TCRs) targeting cancer-testis antigens, such as Melanoma-associated antigen 3 (MAGE-A3), is a potential approach for the treatment of NSCLC. However, systematic analysis of T cell immune responses to MAGE-A3 antigen and corresponding antigen-specific TCR is still lacking. Methods: In this study, we comprehensively screened HLA-A2 restricted MAGE-A3 tumor epitopes and characterized the corresponding TCRs using in vitro artificial antigen presentation cells (APC) system, single-cell transcriptome and TCR V(D)J sequencing, and machine-learning. Furthermore, the tumor-reactive TCRs with killing potency was screened and verified. Results: We identified the HLA-A2 restricted T cell epitopes from MAGE-A3 that could effectively induce the activation and cytotoxicity of CD8+ T cells using artificial APC in vitro. A cohort of HLA-A2+ NSCLC donors demonstrated that the number of epitope specific CD8+ T cells increased in NSCLC than healthy controls when measured with tetramer derived from the candidate MAGE-A3 epitopes, especially epitope Mp4 (MAGE-A3: 160-169, LVFGIELMEV). Statistical and machine-learning based analyses demonstrated that the MAGE-A3-Mp4 epitope-specific CD8+ T cell clones were mostly in effector and proliferating state. Importantly, T cells artificially expressing the MAGE-A3-Mp4 specific TCRs exhibited strong MAGE-A3+ tumor cell recognition and killing effect. Cross-reactivity risk analysis of the candidates TCRs showed high binding stability to MAGE-A3-Mp4 epitope and low risk of cross-reaction. Conclusions: This work identified candidate TCRs potentially suitable for TCR-T design targeting HLA-A2 restricted MAGE-A3 tumor antigen.

Advancement in Research of Melanoma Antigen

Advances in Research of MAGE-A3

Melanoma Antigen Gene Family in the Cancer Immunotherapy

Research Advance of MAGE-A Gene Family in Tumor Growth

Research progress on MAGE-A1

Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.

Expression of Melanoma Antigen Gene in Cell Lines Originated from Hepatocellular Carcinoma Cells

[Biological Functions of Melanoma-Associated Antigens (mages) in Cell Activities].

Biological functions of melanoma-associated antigens.

Research Advances in the Treatment of Melanoma by Treat Melanoma.

Expression of Melanoma Antigen-1,3 Gene in Rectal Cancer and Their Clinical Significance

Magea10 Gene Expression In Non-Small Cell Lung Cancer And A549 Cells, And The Affinity Of Epitopes With The Complex Of Hla-A*0201 Alleles

Maged1: Molecular Insights And Clinical Implications

Tissue Expression Profile of Human MAGE-D1, the New Member of Melanoma Antigen-encoding Gene Family

Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer

Expression of MAGE-A10 Protein and Its Clinical Significance in Human Lung Cancer

Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer

Identification of a New MAGE-A10 Antigenic Peptide Presented by HLA-A*0201 on Tumor Cells

Expression of melanoma antigen gene-3(MAGE-3)in gastric neoplasm and its clinical significance

Development of Ligands and Degraders Targeting MAGE-A3

Expression of MAGE-A1 and Its Clinical Signficance in Hepatocellular Carcinoma